Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2021 16:32 ET | Source: AnaptysBio, Inc.

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSKJEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April...
August 09, 2021 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 MeetingImsidolimab GALLOP GPP Phase 2 trial 16-week data to be orally presented at the...
May 27, 2021 16:15 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
May 04, 2021 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with...
April 23, 2021 10:31 ET | Source: AnaptysBio, Inc.

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to...
April 22, 2021 16:12 ET | Source: AnaptysBio, Inc.

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to...
April 12, 2021 16:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
March 08, 2021 08:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpointImsidolimab was generally well tolerated and no...
February 25, 2021 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated...
January 07, 2021 16:15 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...